The founders of Grace Bio-Labs initiated their scientific careers with cancer research, and we continue to follow this literature with great interest. An interesting article in NY Times recently reported on a new strategy in cancer therapies being pursued by several major pharmaceutical companies.It has long been known that de-regulation of p53 protein is a key factor in the uncontrolled proliferation of cancer cells. Now therapeutic strategies are addressing the mechanism of p53 regulation with small molecules that interrupt its interaction with MDM2. Delivery of small peptides to target cells remains as a key roadblock to new therapies. Not only must the drug function in cultured cells, it must be delivered to the correct cells through human physiological barriers. In any case, the theory that disruption of p53-MDM2 interaction alone will be a universal treatment for cancers remains to be seen. We celebrate the successes of all our customers. Today we acknowledge the research of Amy Rowat and colleagues at the Harvard School of Engineering and Applied Sciences on p53 and MDM2 interactions, published in 2009 in PNAS, titled: “Tracking lineages of single cells in lines using a microfluidic device.” Another example of our products used to create simple and effective chambers for novel imaging applications.